Through the World Health Assembly (WHA), member states have discussed practical steps for greater coordination of research, including the establishment of a global health observatory for monitoring and tracking research. Progress on the observatory and the establishment of a Global Expert Committee for Health Research and Development will be discussed with the WHO in early 2017.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4123", "label" : {"_value" : "Biography information for Lord Wharton of Yarm"} } , "answeringMemberConstituency" : {"_value" : "Stockton South"} , "answeringMemberPrinted" : {"_value" : "James Wharton"} , "dateOfAnswer" : {"_value" : "2016-12-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-12-06T14:46:29.997Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "20"} , "answeringDeptShortName" : {"_value" : "International Development"} , "answeringDeptSortName" : {"_value" : "International Development"} , "date" : {"_value" : "2016-12-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "UN High-level Panel on Access to Medicines"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for International Development, with reference to the UN High-Level Panel on Access to Medicines report published in September 2016, what progress her Department has made with other governments on establishing a global agreement on research and development.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1596", "label" : {"_value" : "Biography information for Dr Alasdair McDonnell"} } , "tablingMemberConstituency" : {"_value" : "Belfast South"} , "tablingMemberPrinted" : [{"_value" : "Dr Alasdair McDonnell"} ], "uin" : "55941"} , {"_about" : "http://data.parliament.uk/resources/649480", "AnsweringBody" : [{"_value" : "Department for International Development"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/649480/answer", "answerText" : {"_value" : "
DFID supports the aims of the UN High Level Panel on Access to Medicines, but we note that this panel of experts could not reach consensus. The World Health Organisation has analysed the barriers that limit access to medicines, and developed a Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. It is, therefore, well-placed to consider, with partners, which of the Panel\u2019s recommendations add value.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4123", "label" : {"_value" : "Biography information for Lord Wharton of Yarm"} } , "answeringMemberConstituency" : {"_value" : "Stockton South"} , "answeringMemberPrinted" : {"_value" : "James Wharton"} , "dateOfAnswer" : {"_value" : "2016-12-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-12-06T14:47:01.757Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "20"} , "answeringDeptShortName" : {"_value" : "International Development"} , "answeringDeptSortName" : {"_value" : "International Development"} , "date" : {"_value" : "2016-12-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "UN High-level Panel on Access to Medicines"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for International Development, what steps the Government is taking on implementing the recommendations in the UN High-Level Panel on Access to Medicines report published in September 2016; and what the timescale is for that implementation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1596", "label" : {"_value" : "Biography information for Dr Alasdair McDonnell"} } , "tablingMemberConstituency" : {"_value" : "Belfast South"} , "tablingMemberPrinted" : [{"_value" : "Dr Alasdair McDonnell"} ], "uin" : "55942"} , {"_about" : "http://data.parliament.uk/resources/476450", "AnsweringBody" : [{"_value" : "Department for International Development"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/476450/answer", "answerText" : {"_value" : "
The UK is committed to ensuring access to low cost, effective medicines in the developing world, providing a range of other significant inputs to increasing access to essential medicines.<\/p>
<\/p>
A new £1 billion fund \u2013 the Ross Fund - was recently announced with the aim of developing, testing and delivering a range of new products to help combat the world\u2019s most serious diseases, such as malaria, Ebola and TB in developing countries.<\/p>
<\/p>
We support the provision of essential medicines and other health products through innovative global partnerships such as the Global Fund to fight AIDS, TB and Malaria, UNITAID, Gavi, the Vaccine Alliance and the Medicines Patent Pool (MPP). We work to strengthen systems weaknesses, such as weak supply chains or poor procurement, which deter private investment, keep medicines prices high or lead to misuse or waste of medicines. We also place a great emphasis on research and development of new vaccines, medicines and diagnostics for conditions that affect millions of poor people. For example, the UK is a leading investor in public-private Product Development Partnerships (PDPs), designed to stimulate research and development (R&D) where market incentives are insufficient.<\/p>
<\/p>
We support the aims of the UN High Level Panel on Access to Medicines. For it to fulfil its potential to improve access to affordable and quality medicines it will need to take a balanced approach, building and urge them to build on the WHO Global Strategy and Plan of Action (including underlying in-depth reports and discussions), and engaging withe existing global partnerships, and use its influence to galvanise Member States, public and private sectors around a common approach to this important issue.<\/p>
<\/p>
<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3790", "label" : {"_value" : "Biography information for Baroness Verma"} } , "answeringMemberPrinted" : {"_value" : "Baroness Verma"} , "dateOfAnswer" : {"_value" : "2016-03-31", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2016-03-31T15:02:45.02Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "20"} , "answeringDeptShortName" : {"_value" : "International Development"} , "answeringDeptSortName" : {"_value" : "International Development"} , "date" : {"_value" : "2016-03-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "UN High-level Panel on Access to Medicines"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what assessment they have made of the mandate of the UN Secretary General\u2019s High Level Panel on Access to Medicines and its potential to improve access to affordable and quality medicines across the world.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2501", "label" : {"_value" : "Biography information for Baroness Barker"} } , "tablingMemberPrinted" : [{"_value" : "Baroness Barker"} ], "uin" : "HL7029"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }